Upstream Bio (NASDAQ:UPB) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Upstream Bio (NASDAQ:UPB) issued its quarterly earnings data on Wednesday. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.04, reports. The company had revenue of $1.03 million during the quarter, compared to the consensus estimate of $0.62 million. Upstream Bio had a negative net margin of 5,026.03% and a negative return on equity of 36.48%.

Upstream Bio Trading Down 4.1%

UPB stock opened at $8.98 on Thursday. Upstream Bio has a 12-month low of $7.25 and a 12-month high of $33.68. The business’s 50-day moving average is $9.20 and its 200 day moving average is $19.36. The stock has a market cap of $488.69 million, a price-to-earnings ratio of -3.43 and a beta of 1.28.

Institutional Trading of Upstream Bio

A number of institutional investors have recently made changes to their positions in the company. Empowered Funds LLC purchased a new stake in shares of Upstream Bio during the fourth quarter worth approximately $45,000. Russell Investments Group Ltd. boosted its stake in Upstream Bio by 1,963.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock worth $57,000 after purchasing an additional 2,887 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Upstream Bio by 229.8% during the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after buying an additional 2,158 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Upstream Bio by 83.0% during the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after buying an additional 1,440 shares in the last quarter. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Upstream Bio in the fourth quarter valued at about $242,000.

Analyst Upgrades and Downgrades

UPB has been the topic of several research reports. Wall Street Zen downgraded shares of Upstream Bio from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Weiss Ratings cut Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Evercore downgraded Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price target on the stock. in a research report on Friday, March 27th. Finally, Mizuho decreased their target price on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Upstream Bio presently has a consensus rating of “Hold” and a consensus target price of $38.75.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.